Researchers at the Toronto Western Hospital (TWH) Liver Clinic have found that a simple drug regimen delivered over 12 weeks achieved sustained eradication of several genotypes of the hepatitis C virus (HCV) in 99 per cent of the trial’s patients.
The study, released today in the New England Journal of Medicine, showed that receiving a once daily drug combination of sofosbuvir-velpatasvir for a 12 week period was effective in both treatment-naïve and previously treated patients with HCV genotype 1, 2, 4, 5, or 6, including those with compensated cirrhosis (where scarring of the liver has occurred but patients have yet to experience symptoms as a result of it).
“This drug regimen changes the standard of care in treating patients with HCV – we can now cure almost everyone with a very simple treatment,” said Dr. Jordan Feld, Hepatologist, Francis Family Liver Clinic, TWH and the first author of the study. “It’s incredibly gratifying to be part of research where we not only cure a disease but can also think about eliminating HCV in Canada.”
Current approved treatments for chronic HCV are not equally effective in combating the virus’ different genotypes. Testing to determine the genotype and subtype of the virus is required before treatment could be initiated. But the combination of sofosbuvir-velpatasvir has been shown to be applicable to all strains of HCV, effectively eliminating the need to test for the viral genotype – an obstacle that often delayed treatment.
The regimen was tested in an international, randomized, double-blind placebo-controlled phase three trial conducted at 81 sites in eight different countries. After 12 weeks, 99 per cent of the 624 patients who had been treated with a daily tablet of sofosbuvir-velpatasvir experienced a sustained virologic response – the medical term for eradication or cure of HCV – meaning that patients remained free of the virus three months after completing treatment. None of the 116 patients receiving a placebo experienced the same result.
“This is truly a one size fits all treatment that is very easy to administer and extremely well tolerated,” said Dr. Feld. “Our challenge now is getting treatment to those who need it. Over half of people living with hepatitis C remain undiagnosed. Fortunately this regimen, along with other advances in therapy, will allow us to move treatment out of specialty clinics so that we can deliver care and ideally cure all infected Canadians.”
Chronic HCV is known as a “silent” killer because symptoms often don’t appear until the liver is severely damaged. Left undiagnosed, HCV can lead to cirrhosis which can progress to liver failure or liver cancer. HCV is primarily spread by blood-to-blood contact and is associated with intravenous drug use, contact with poorly sterilized medical equipment and blood transfusions before 1992.
Approximately 170 million people are infected with chronic HCV worldwide with an estimated 252,000 in Canada. HCV causes the greatest burden of disease, measured in years of life lost, than any infectious disease in Canada.?
The Latest on: Hepatitis C
via Google News
The Latest on: Hepatitis C
- Hepatitis C in London: annual reportson January 22, 2020 at 2:14 pm
Please tell us what format you need. It will help us if you say what assistive technology you use. The aim of these reports is to describe the epidemiology of hepatitis C in London. The reports ...
- Hepatitis C virus infection suppresses hepatitis B virus replication via the RIG-I-like helicase pathwayon January 22, 2020 at 2:14 am
Mechanisms of hepatitis B virus (HBV) reactivation after hepatitis C virus (HCV) elimination by direct-acting antiviral (DAA) treatment in HBV/HCV-co-infected patients remain unclear. We examined ...
- Transplant Recipients Receive Organs From Donors Who Had Hepatitis Con January 21, 2020 at 5:28 pm
Some of the top transplant programs in the country are addressing the shortage by accepting hearts from donors who had active hepatitis C. Recipients know going in they will get the disease, but, so ...
- Prioritizing Your Hepatitis C virus (HCV) Testing Market To Get The Most Out Of Your Business, From 2018-2027on January 21, 2020 at 1:09 am
Recent report published by research nester titled "Global Hepatitis C Virus (HCV) Testing Market: Global ...
- Hepatitis C-infected heart transplants can save lives, new statistics showon January 20, 2020 at 5:24 pm
Some of the top transplantation programs in the country are now addressing a shortage heart transplants by accepting hearts from donors who had active Hepatitis C.
- Hepatitis C Drug Market Development, Key Opportunity, Application and Forecast to 2026on January 19, 2020 at 11:26 pm
Hepatitis C Drug Market to Witness Huge Growth by 2026 | Leading Key Players AbbVie Inc., Gilead Sciences, Inc., Bristol-Myers Squibb Company, Janssen Pharmaceuticals, Inc., Merck Sharp & Dohme Corp., ...
- HepVu Launches New Data Visualizing Hepatitis C's Impact on Americans of Different Ages, Sexes, and Raceson January 16, 2020 at 8:54 am
HepVu today launched new interactive maps illustrating the prevalence of Hepatitis C in the United States between 2013 and 2016, stratified at the state-level by age, sex, and race. Published in ...
- Global Hepatitis C Drugs Market Size and Share Worth US$ 10,110.4 Million | CAGR of 4.0 % By 2027 – Coherent Market Insightson January 16, 2020 at 12:13 am
According to Coherent Market Insights, the global hepatitis C drugs market was valued at US$ 7,376.6 million in 2019 and is expected to exhibit a CAGR of 4.0 % over the forecast period (2019 – 2027).
- Judge gives preliminary approval for hepatitis C testing and treatment for all SC inmateson January 14, 2020 at 1:32 pm
South Carolina moved one step closer this week to the legally mandated testing and treatment of all inmates for hepatitis C. In 2017, plaintiffs Russell Geissler, Bernard Bagley and Willie James ...
- Multi-million dollar settlement in SC prison hepatitis C case gets initial approvalon January 14, 2020 at 8:56 am
A multi-million dollar class action lawsuit brought by inmates at the S.C. Department of Corrections over a lack of treatment for potentially fatal Hepatitis C received initial approval by a federal ...
via Bing News